BRPI0913736A2 - Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central - Google Patents
Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso centralInfo
- Publication number
- BRPI0913736A2 BRPI0913736A2 BRPI0913736A BRPI0913736A BRPI0913736A2 BR PI0913736 A2 BRPI0913736 A2 BR PI0913736A2 BR PI0913736 A BRPI0913736 A BR PI0913736A BR PI0913736 A BRPI0913736 A BR PI0913736A BR PI0913736 A2 BRPI0913736 A2 BR PI0913736A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- treatment
- pharmaceutical composition
- nervous system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/30—Nitrogen atoms non-acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
COMPOSTO, PROCESSO PARA A PREPARAÇÃO DO COMPOSTO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA O TRATAMENTO DE UMA DESORDEM DO SISTEMA NERVOSO CENTRAL A presente invenção refere-se a novos compostos amina aril sulfonamida tendo a fórmula (I), suas formas tautoméricas, seus estereoisômeros, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis aqui descritos e às composições farmaceuticamente aceitáveis contendo os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2264CH2008 | 2008-09-17 | ||
PCT/IN2009/000145 WO2010032258A1 (en) | 2008-09-17 | 2009-03-03 | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0913736A2 true BRPI0913736A2 (pt) | 2023-04-11 |
Family
ID=41058612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0913736A BRPI0913736A2 (pt) | 2008-09-17 | 2009-03-03 | Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central |
Country Status (20)
Country | Link |
---|---|
US (1) | US8404720B2 (pt) |
EP (1) | EP2346847B1 (pt) |
JP (1) | JP5536781B2 (pt) |
KR (1) | KR101308819B1 (pt) |
CN (1) | CN102159564B (pt) |
AU (1) | AU2009294181B2 (pt) |
BR (1) | BRPI0913736A2 (pt) |
CA (1) | CA2737282C (pt) |
CY (1) | CY1114196T1 (pt) |
DK (1) | DK2346847T3 (pt) |
EA (1) | EA019496B1 (pt) |
ES (1) | ES2424036T3 (pt) |
HK (1) | HK1159626A1 (pt) |
HR (1) | HRP20130721T1 (pt) |
IL (1) | IL211747A (pt) |
MX (1) | MX2011002884A (pt) |
NZ (1) | NZ591833A (pt) |
SI (1) | SI2346847T1 (pt) |
WO (1) | WO2010032258A1 (pt) |
ZA (1) | ZA201101955B (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102358735B (zh) * | 2011-08-23 | 2013-09-04 | 范如霖 | 低毒性的多头分导药,带羟基或取代羟基的含氮芳环cb1受体抑制剂及其制药用途 |
RU2705595C2 (ru) * | 2015-07-06 | 2019-11-11 | Паблик Юниверсити Корпорейшн Йокогама Сити Юниверсити | Новое соединение, специфически связывающееся с рецептором ampa |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
JP2002511097A (ja) | 1997-07-11 | 2002-04-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht▲下6▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 |
GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
ATE375990T1 (de) | 1999-04-21 | 2007-11-15 | Nps Allelix Corp | Piperidin-indol derivate mit 5-ht6 affinität |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
BR0115102B1 (pt) | 2000-11-02 | 2013-11-26 | Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos | |
DE60214990T2 (de) | 2001-01-30 | 2007-04-05 | Eli Lilly And Co., Indianapolis | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten |
BR0207302A (pt) | 2001-02-08 | 2004-02-10 | Memory Pharm Corp | Trifluorometilpurinas como inibidores da fosfodiesterase 4 |
ES2280546T3 (es) | 2001-06-07 | 2007-09-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de indol con afinidad por el receptor 5-ht6. |
US20040242589A1 (en) | 2001-08-07 | 2004-12-02 | Bromidge Steven Mark | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
AU2003238339A1 (en) | 2002-02-01 | 2003-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
AU2003244452A1 (en) | 2002-02-05 | 2003-09-02 | Glaxo Group Limited | Method of promoting neuronal growth |
JP4455064B2 (ja) | 2002-03-27 | 2010-04-21 | グラクソ グループ リミテッド | キノリン誘導体および5−ht6リガンドとしてのその使用 |
AU2003237599B2 (en) | 2002-11-28 | 2009-06-18 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
NZ540842A (en) | 2002-11-28 | 2008-05-30 | Suven Life Sciences Ltd | N-arylsulfonyl-3-aminoalkoxyindoles |
AU2003292508A1 (en) | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
DK1581538T3 (da) | 2002-12-18 | 2007-06-25 | Suven Life Sciences Ltd | Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet |
WO2004108671A1 (en) | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
ES2222828B1 (es) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
US7223759B2 (en) * | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
AU2004299438A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder |
WO2005066157A1 (en) | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
WO2007020653A1 (en) | 2005-08-12 | 2007-02-22 | Suven Life Sciences Limited | Thioether derivatives as functional 5-ht6 ligands |
WO2007046112A1 (en) | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
WO2007138611A1 (en) | 2006-05-30 | 2007-12-06 | Suven Life Sciences Limited | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands |
-
2009
- 2009-03-03 KR KR1020117007664A patent/KR101308819B1/ko active IP Right Grant
- 2009-03-03 SI SI200930678T patent/SI2346847T1/sl unknown
- 2009-03-03 MX MX2011002884A patent/MX2011002884A/es active IP Right Grant
- 2009-03-03 NZ NZ591833A patent/NZ591833A/en not_active IP Right Cessation
- 2009-03-03 DK DK09787575.1T patent/DK2346847T3/da active
- 2009-03-03 WO PCT/IN2009/000145 patent/WO2010032258A1/en active Application Filing
- 2009-03-03 CA CA2737282A patent/CA2737282C/en not_active Expired - Fee Related
- 2009-03-03 US US13/063,436 patent/US8404720B2/en not_active Expired - Fee Related
- 2009-03-03 CN CN200980136111.2A patent/CN102159564B/zh not_active Expired - Fee Related
- 2009-03-03 BR BRPI0913736A patent/BRPI0913736A2/pt not_active IP Right Cessation
- 2009-03-03 ES ES09787575T patent/ES2424036T3/es active Active
- 2009-03-03 AU AU2009294181A patent/AU2009294181B2/en not_active Ceased
- 2009-03-03 EP EP09787575.1A patent/EP2346847B1/en active Active
- 2009-03-03 JP JP2011527471A patent/JP5536781B2/ja not_active Expired - Fee Related
- 2009-03-03 EA EA201170461A patent/EA019496B1/ru not_active IP Right Cessation
-
2011
- 2011-03-15 IL IL211747A patent/IL211747A/en active IP Right Grant
- 2011-03-15 ZA ZA2011/01955A patent/ZA201101955B/en unknown
-
2012
- 2012-01-06 HK HK12100158.4A patent/HK1159626A1/xx not_active IP Right Cessation
-
2013
- 2013-08-01 HR HRP20130721AT patent/HRP20130721T1/hr unknown
- 2013-08-06 CY CY20131100666T patent/CY1114196T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EA201170461A1 (ru) | 2011-10-31 |
IL211747A (en) | 2014-11-30 |
US8404720B2 (en) | 2013-03-26 |
KR101308819B1 (ko) | 2013-09-13 |
CA2737282A1 (en) | 2010-03-25 |
CN102159564A (zh) | 2011-08-17 |
EP2346847A1 (en) | 2011-07-27 |
CA2737282C (en) | 2014-03-25 |
HK1159626A1 (en) | 2012-08-03 |
HRP20130721T1 (en) | 2013-09-30 |
DK2346847T3 (da) | 2013-08-05 |
EP2346847B1 (en) | 2013-05-15 |
AU2009294181A1 (en) | 2010-03-25 |
JP5536781B2 (ja) | 2014-07-02 |
JP2012502982A (ja) | 2012-02-02 |
EA019496B1 (ru) | 2014-04-30 |
IL211747A0 (en) | 2011-06-30 |
WO2010032258A1 (en) | 2010-03-25 |
CN102159564B (zh) | 2014-06-18 |
KR20110049917A (ko) | 2011-05-12 |
CY1114196T1 (el) | 2016-08-31 |
NZ591833A (en) | 2012-02-24 |
US20120129816A1 (en) | 2012-05-24 |
AU2009294181B2 (en) | 2011-11-17 |
MX2011002884A (es) | 2011-04-21 |
ES2424036T3 (es) | 2013-09-26 |
ZA201101955B (en) | 2011-12-28 |
SI2346847T1 (sl) | 2013-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
ECSP22047876A (es) | Derivados de pirazolilo ?tiles como agentes anticancer?genos | |
BR112022008375A2 (pt) | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste | |
BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
BR112017009194A2 (pt) | tetra-hidropiranos substituídos e método de uso | |
BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
BR112017010354B8 (pt) | Compostos de triazolopirimidina, seu uso, e composição farmacêutica | |
CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
BR112016016844A2 (pt) | Compostos heterocíclicos | |
BR112019003932A2 (pt) | composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
CY1113339T1 (el) | Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες | |
AR110128A2 (es) | Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo | |
BR112020012712A8 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc | |
BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
DOP2010000374A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 12A, 13A E 14A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2728 DE 18/04/2023. |